# KLINIKOS EXECUTIVE OPERATING SNAPSHOT — 2026-08-25

Status: CURRENT-STATE EXECUTIVE HANDOFF
Snapshot date: 2026-08-25
Base repository main observed at snapshot start: `1722955c2143d11ef7220f6cc3c316224fea6a5e`

This file operationalizes, but does not replace:

- `governance/KLINIKOS_COMPANY_OPERATING_SYSTEM.md`
- `src/lib/company-operating-canon.ts`
- `governance/KLINIKOS_COMPANY_CONTROL_REGISTERS.md`
- `governance/KLINIKOS_EXECUTIVE_REVIEW_GAUNTLET.md`
- `CLAUDE.md`

It is a dated executive snapshot, not a permanent source of live external truth.

## 1. Executive conclusion

The current company bottleneck is not lack of architecture.

Klinikos already has unusually broad product, clinical, commercial, network, EDU, governance and company-operating architecture.

The current dependency order is:

`RESTORE PRODUCTION → WIN/LAUNCH ONE REAL PILOT → MEASURE VALUE → CONVERT PROOF INTO SALES / CANCERX / CAPITAL EVIDENCE → CONTINUE GOLDEN CLINICAL CASE → PROTECT RELEASE PATH → SCALE DISTRIBUTION`

The two highest-value company outcomes now are:

1. restore a trustworthy production surface; and
2. obtain one real customer/pilot result with `BEFORE → ACTION → AFTER → EVIDENCE`.

Do not let new strategy, broad feature expansion, marketplace payments, or vanity outreach interrupt those dependencies unless a safety, paying-customer, revenue-activation, or reusable-platform blocker requires it.

## 2. Current fact register

| Record | Truth class | Current fact | Evidence location | Status | Next action |
| --- | --- | --- | --- | --- | --- |
| REPO-001 | CURRENT_FACT | Repository `main` was observed at `1722955c2143d11ef7220f6cc3c316224fea6a5e` during this snapshot. | GitHub branch metadata | current at observation | re-read before any merge/release because main is moving quickly |
| GOV-001 | EXECUTED | Company Operating System, machine-readable company canon, control-register canon, executive review gauntlet and agent read-order are installed on `main`. | governance files, `src/lib/company-operating-canon.ts`, `CLAUDE.md` | installed | use them for every material cycle rather than creating parallel strategy |
| PROD-001 | CURRENT_FACT | `https://www.klinikos.io/` returned HTTP 503 during this operating review. | direct web fetch on 2026-08-25 | critical blocker | execute reviewed production migration reconciliation and verify deployed SHA |
| REPO-002 | CURRENT_FACT | GitHub reports `main` unprotected with required status checks disabled. | GitHub branch metadata; issue #226 | major governance risk | restore executable CI/runner path, then protect main with real required checks |
| CRM-001 | CURRENT_FACT | Connected HubSpot contains 8 companies total: 7 real Klinikos target companies plus the original HubSpot sample company. | connected HubSpot read on 2026-08-25 | structured target universe | promote only genuine commercial events into deals |
| CRM-002 | CURRENT_FACT | Connected HubSpot contains 0 deals. | connected HubSpot DEAL read on 2026-08-25 | no qualified deal objects yet | create a deal only after a real qualifying event; do not promote outreach alone |
| SALES-001 | EXECUTED | Direct $500 Clinic Operating Analysis follow-ups were sent to multiple clinic targets, including Hudson Medical, Spine & Pain, Groth Pain & Spine, Pelvic Rehabilitation Medicine and Abilities In Action. | connected Outlook sent-mail evidence | outbound executed | monitor replies/checkout evidence; avoid duplicating messages |
| CX-001 | CURRENT_FACT | CancerX Accelerator replied that Klinikos sounds like a strong fit, copied its Associate Director, and invited a fit conversation. | connected Outlook inbound message; issue #317 | high-value active opportunity | complete fit conversation and align one real pilot proof with application eligibility |
| ROOTS-001 | CURRENT_FACT | NC ROOTS / Impact Health replied that regional scope and contracting are still being finalized and partner engagement is expected in coming months. | connected Outlook inbound message | future partner lane | preserve relationship without claiming contract, customer or awarded status |
| CLIN-001 | EXECUTED | Current main contains distinct medical assistant, licensed practical nurse and registered nurse application roles with conservative authority separation. | merged PR #311 / current repo | built | capture recorder provenance in persistence after production migration blocker is cleared |
| CLIN-002 | EXECUTED | Staff Handoff now has an explicit attribution contract that refuses to invent a recorder/role when not stored. | merged PR #312 / current repo | built contract | wire persisted recorder provenance and presentation |
| CLIN-003 | EXECUTED | Clinical Change now derives deterministic BodyMap comparison states instead of relying on a constant placeholder. | merged PR #313 / current repo | built derivation | load real BodyMap history into Current Visit and present per-finding deltas |
| PR-257 | CURRENT_FACT | Zumi Memory & Knowledge PR #257 still contains unique unmerged memory-authority implementation. | GitHub PR #257 | preserve/re-anchor | extract smallest unique tranche onto current main after production recovery |
| PR-282 | CURRENT_FACT | Universal Account/free-member PR #282 still contains unique unmerged account foundation; current main does not contain `universal-account.prisma`. | GitHub PR #282 | preserve/re-anchor | reconcile with newer Access/Identity/Agreements/IP/Trust canon before merge |
| PR-294 | CURRENT_FACT | Workforce PR #294 still contains unique unmerged workforce configuration/evidence-chain/demo/EDU→Grid implementation. | GitHub PR #294 | preserve/re-anchor | extract unique tranche from stale stacked base after production recovery |

## 3. Evidence currently unavailable or not refreshed

### Stripe live financial truth

The currently connected Stripe session exposed only the `KLINIKOS.IO sandbox` account during this snapshot.

Therefore this snapshot does **not** refresh or assert current live:

- payment intent count
- subscription count
- live balance
- live cash received
- MRR
- ARR

Historical live Stripe observations from earlier operating reviews must not be silently treated as current financial truth.

Required next step when the live account is available again:

`READ LIVE STRIPE → RECONCILE PAYMENT EVIDENCE → UPDATE FINANCE/CRM TRUTH → PRESERVE DATE/SOURCE`

### Company-wide cash and runway

No complete current bank/accounting read was performed in this snapshot.

Therefore current cash, burn, AR, debt, booked revenue, gross margin and runway remain UNKNOWN here.

Do not derive runway from founder narrative, hypothetical valuation, Stripe sandbox data, or proposed funding.

## 4. Active P0 register

### P0-A — Production recovery

Owner: engineering/platform + human production credential holder
GitHub: #316

Problem:

The public site is unavailable and the reviewed release architecture is blocked by production migration reconciliation.

Why it outranks almost everything:

- damages buyer trust
- weakens outbound conversion
- weakens demo credibility
- prevents proof that newer merged product work is actually live
- makes website/SEO acquisition meaningless while unavailable
- creates uncertainty between repository truth and production truth

Required success evidence:

1. reviewed production migration state reconciled;
2. no failed/half-applied migration;
3. Render deploy succeeds through approved path;
4. `/api/health` succeeds;
5. `klinikos.io` serves product instead of 503;
6. deployed SHA is proven;
7. critical public/authenticated journeys smoke-tested;
8. PHI readiness remains separately gated.

Do not bypass this with a forced deploy or migration-ledger fabrication.

### P0-B — First real customer/pilot proof

Owner: sales/commercial + implementation/customer success + founder
GitHub: #305

Target path:

`QUALIFIED PROBLEM → $500 ANALYSIS / BOUNDED PILOT → IMPLEMENTATION → FIRST VALUE → BEFORE/ACTION/AFTER/EVIDENCE → EXPANSION`

Success is not email volume.

Success is either:

- a provider-confirmed paid/pilot event with measurable value evidence; or
- a documented no-sale result that identifies a causal blocker and changes ICP, pricing, proof, implementation or product strategy.

This proof is also a dependency for stronger accelerator, investor, grant and enterprise claims.

## 5. P0/P1 strategic opportunity register

### CancerX 2027

Truth class: CURRENT_FACT opportunity + PROPOSED application path
GitHub: #317

Current evidence:

- CancerX gave explicit positive fit feedback.
- A fit conversation was invited.
- Klinikos must not invent oncology validation.

Best use:

Use one real operational pilot outside or inside oncology to prove a reusable workflow primitive, then translate carefully into an oncology operating use case only where the evidence supports it.

Potential primitive families:

- unfinished-work ownership
- intake/readiness
- patient outreach
- staff handoff
- authorization/referral/result visibility
- care coordination
- administrative operating backbone
- governed operational intelligence

Hard gate:

No oncology deployment, patient-outcome, CancerX partnership or acceptance claim without direct evidence.

### NC ROOTS / Impact Health

Truth class: CURRENT_FACT relationship; PROPOSED future partner path

Current interpretation:

Potential public-sector/regional-network relationship, not current contracted revenue.

Next action:

Remain in the partner/vendor lane and re-engage when scope/contracting becomes concrete.

Do not spend current P0 engineering capacity building speculative ROOTS-specific product.

## 6. Commercial truth register

### Current target-company universe in HubSpot

Real target companies currently structured in HubSpot include:

- Lincroft Oral & Maxillofacial Surgery
- Professional Orthopaedic Associates
- Abilities In Action Pediatric Therapy
- Bluehouse Eyecare
- Robert Wood Johnson University Hospital in New Brunswick
- Hudson Medical
- The Spine & Pain Institute of New York

The original HubSpot sample company remains non-Klinikos sample data.

### Deal rule

A company record is not a deal.

An outbound email is not a deal.

A reply is not automatically a deal.

A deal requires enough evidence to record a real:

- buyer / buying process
- problem
- stage
- next action
- owner
- plausible offer/value
- amount when supportable

HubSpot currently has zero deal records and that number must remain zero until a qualifying commercial event exists.

## 7. Product / clinical convergence register

The doctor-defined acceptance path remains the clinical proof target.

Current sequence:

`PATIENT SNAPSHOT → WHAT CHANGED → STAFF HANDOFF → TODAY → CLINICAL → ASSESSMENT & PLAN → ORDERS/RESULTS → DOCUMENTATION/CODING → CLOSE VISIT`

Current strongest next slices:

1. persist actual recorder provenance for measurements/clinical intake;
2. load BodyMap versions into Current Visit context;
3. render per-finding `INITIAL → PREVIOUS → TODAY` evidence;
4. preserve explicit resolution only;
5. finish Golden Provider Case across handoff, visit, orders/results, documentation/coding and close;
6. retain provider signature and human clinical authority;
7. keep AI as governed draft/explanation support rather than authority.

Do not restart this as a second clinical module.

## 8. Preserved unmerged implementation register

### PR #257 — Zumi Memory & Knowledge

Decision: MODIFY / RE-ANCHOR

Reason:

The capability aligns with the final ecosystem and still contains unique code, but the branch predates newer Zumi, server-boundary and company-governance canons.

### PR #282 — Universal Account / Free Member

Decision: MODIFY / RE-ANCHOR

Reason:

Free identity is strategically useful for distribution and Grid/EDU/network growth, but auth, agreements, rate limits, current lifelong identity and account authority must converge on one current-main model.

### PR #294 — Workforce Max

Decision: MODIFY / RE-ANCHOR

Reason:

Unique evaluator/workforce implementation exists, but its stacked architecture base is stale and later EDU authority/security repairs outrank the old assumptions.

### Closed stale branch

PR #288 was correctly closed because newer BodyMap persistence/change work supersedes it.

## 9. Company risk register — highest current risks

| Risk | Severity | Evidence | Mitigation |
| --- | --- | --- | --- |
| Public production outage / release deadlock | CRITICAL | live site 503; #316 | execute reviewed migration recovery; verify deployed SHA |
| Unprotected main | HIGH | GitHub branch metadata; #226 | restore executable CI then require real checks and PR rules |
| Architecture outrunning paid proof | HIGH | broad built platform + zero HubSpot deals | first real pilot/customer proof before broad expansion |
| External financial truth not continuously reconciled | HIGH | live Stripe account unavailable in current connector session | reconnect/read live source; dated finance snapshot; no stale reuse |
| Clinical recorder provenance incomplete | HIGH for clinical fidelity | #312 explicitly reports recorder not stored | additive provenance capture after production blocker clears |
| Stale open branches could overwrite newer architecture | HIGH | multiple old PRs with divergent bases | supersession audit; close obsolete, re-anchor unique code only |
| Public acquisition while site unavailable | HIGH commercial | 503 | pause traffic-scaling; use direct trusted/warm paths until restored |
| Grid fee/legal risk | HIGH | fee policy counsel gates | keep clinical/referral/professional economics fail-closed until cleared |
| PHI production-readiness overclaim | CRITICAL trust/compliance | separate readiness gate remains unresolved | never claim production PHI readiness until explicitly verified |

## 10. Decision register — current decisions

### DEC-001 — Stop broad strategy expansion as the primary workstream

Decision: STOP as active P0; preserve discovery register only.

Reason:

The company and product architecture are sufficiently broad. Current enterprise value increases more from production availability and customer proof than another umbrella strategy document.

### DEC-002 — Do not mass-scale cold acquisition into a 503 site

Decision: MODIFY acquisition behavior.

Reason:

Continue warm replies, direct paid-service paths and relationship development, but do not intentionally amplify traffic into a broken trust surface.

### DEC-003 — Do not enable Grid Connect/payout economics yet

Decision: DEFER.

Reason:

No need to introduce merchant-of-record, loss, dispute, payout and regulated marketplace complexity before repeat lawful fulfillment and counsel-cleared fee policy exist.

### DEC-004 — Preserve unique stale-branch code, never merge stale architecture wholesale

Decision: MODIFY / RE-ANCHOR.

Reason:

#257, #282 and #294 still contain valuable implementation, but current main is the newer architecture authority.

### DEC-005 — Treat first customer proof as a multi-purpose enterprise-value asset

Decision: BUILD / TEST.

One measured pilot should be designed so the resulting evidence can support:

- commercial conversion
- product prioritization
- customer-value evidence
- implementation benchmark
- CancerX eligibility/application evidence
- investor diligence
- grants/procurement
- enterprise sales

without changing the underlying facts for each audience.

## 11. Next five dependency-ordered actions

### 1. Restore production

Complete #316 through the reviewed human-controlled migration path and prove the deployed SHA.

### 2. Convert one real clinic problem into paid/pilot proof

Use the existing $500 / audit / sprint / implementation ladder or a bounded pilot where appropriate.

Capture:

`BASELINE → INTERVENTION → AFTER → EVIDENCE → CUSTOMER CONFIRMATION`

### 3. Complete CancerX fit conversation

Extract the exact operational/champion problem and record it as customer/program evidence, not speculative oncology product scope.

### 4. Finish Golden Current Visit evidence path

Prioritize recorder provenance and real BodyMap history composition over unrelated clinical feature expansion.

### 5. Repair release governance

Once executable CI is available, protect `main` and make required checks real rather than symbolic.

## 12. Daily operating review contract

Every daily company pass should answer, from current sources where available:

1. Is production healthy?
2. Did money actually move?
3. Did a target become a qualified opportunity?
4. Did a customer/pilot move closer to first value?
5. Did any security, privacy, clinical, legal or integration risk change?
6. What is the active P0?
7. What should stop today?

If a required source is unavailable, record `UNKNOWN / SOURCE UNAVAILABLE` rather than carrying forward yesterday's number as today's fact.

## 13. Weekly operating review contract

Review:

- shipping and production truth
- cash/revenue evidence
- pipeline
- customer proof
- implementation
- support burden
- acquisition
- Grid active-cell evidence
- EDU institutional pipeline
- capital opportunities
- security/assurance
- stale decisions
- vendor/integration health
- next five actions

Output only evidence-backed changes and dependency decisions.

## 14. Staleness policy

External operational truth decays.

At minimum:

- production availability: re-read every operating cycle where deployment or selling depends on it;
- repository SHA/protection: re-read before merge/release/governance claims;
- CRM pipeline: re-read before pipeline claims;
- payments/cash: re-read from authoritative payment/accounting source before financial claims;
- accelerator/procurement deadlines: re-verify before submission;
- regulatory/legal conditions: re-verify before activating a governed economic/clinical flow;
- integration status: re-read from the authoritative external system before production claims.

Historical evidence remains evidence of history, not current state.

## 15. Executive anti-theater rules

Never call:

- prospect records customers;
- messages sent pipeline;
- replies revenue;
- payment links cash;
- proposed recurring prices MRR;
- coordinated healthcare value Klinikos revenue;
- architecture production readiness;
- adapters live integrations;
- AI output clinical authority;
- training evidence licensure;
- expected contracts executed contracts;
- economic-flow scenarios company valuation.

## 16. Final operating law

The company operating layer is no longer missing.

The next level is not another broader prompt.

It is disciplined conversion of the existing architecture into:

`UPTIME → CUSTOMER PROOF → CASH → FIRST VALUE → REPEAT VALUE → RETENTION → EXPANSION → NETWORK EFFECTS → DEFENSIBLE EVIDENCE`

Every new initiative should be judged by whether it accelerates that sequence without violating truth, safety, professional authority, legal boundaries, capital discipline or architectural coherence.
